
Greenwich LifeSciences, Inc.: stock overview
Price
$19.25
November 20, 2026Market cap $283M
What Ploutos Investor adds for Greenwich LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 40% since Nov 16, 2026, when the 10-Q these figures come from was filed ($13.76 then, $19.25 on Nov 20, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
In short
It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $283M
- 14.68M shares
- P/E
- –
- Revenue, 12 months
- –
- Net margin
- –
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Fiscal years in figures
GLSI's revenue, profit, cash flow and dividend with each year-end price, from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $149M
- $283M
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 164.1
- –
- FCF yield
- –
- Earnings yield 3-year median: -6.8%
- –
Profitability
- Net margin
- –
- ROIC
- –
- ROE
- -1,398.8%
Growth
Sorry, we do not have enough data
for the “Growth” group
Balance sheet
- Cash
- $5.9M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 0.77
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +10.6%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Greenwich LifeSciences, Inc.
- CIK
- 1799788
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 14.68M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with GLSI
- JNJJohnson & Johnson+0,00%Compare with GLSI
- ABBVAbbVie+0,00%Compare with GLSI
- UNHUnitedHealth+0,00%Compare with GLSI
- MRKMerck & Company+0,00%Compare with GLSI
- AMGNAmgen+0,00%Compare with GLSI
- TMOThermo Fisher Scientific+0,00%Compare with GLSI
- ABTAbbott Laboratories+0,00%Compare with GLSI
The full analysis
What do Greenwich LifeSciences's filings show?
These are Greenwich LifeSciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is GLSI's market cap?
Greenwich LifeSciences, Inc.'s market cap is $283M, at a price of $19.25 on November 20, 2026 and 14.68M shares.
Does GLSI pay a dividend?
No. Greenwich LifeSciences paid no regular dividend over the last 12 months.
Where do the figures come from?
From Greenwich LifeSciences, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.